Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 7/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 7/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7974846 | 0.75 | PNMT (0.52) | PNMTITGB3ITGA2BPARP1PARP2 | |
| SCHEMBL22502985 | 0.74 | PNMT (0.43) | PNMTPARP1PARP2 | |
| SCHEMBL1173814 | 0.73 | KDM4E (0.56) | PNMTITGB3ITGA2BPARP1PARP2 | |
| Hydrochloric Acid SCHEMBL27077216 | 0.72 | KDM4E (0.55) | PNMTITGB3ITGA2BPARP1PARP2 | |
| SCHEMBL19642967 | 0.72 | PLAU (0.49) | — | |
| SCHEMBL23460842 | 0.70 | PNMT (0.40) | PNMTPARP1PARP2KCNH2 | |
| Hydrochloric Acid SCHEMBL27149019 | 0.70 | PNMT (0.37) | PNMTITGB3ITGA2BPARP1PARP2 | |
| SCHEMBL31173367 | 0.69 | ESR2 (0.46) | ADORA1 | |
| SCHEMBL13832492 | 0.69 | PNMT (0.48) | PNMTITGB3ITGA2BPARP1PARP2 | |
| SCHEMBL30916151 | 0.68 | ALDH1A1 (0.61) | PNMTITGB3ITGA2BPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692057-A1 | NOVEL B0AT1 INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-01 | — | — | US | disclosed |
| WO-2024210198-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | PNMT 214/4885ITGB3 4504/4885ITGA2B 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.